Druckenmiller's Duquesne Family Office's latest 13F filing, dated August 14, 2026, revealed Natera as his top pick, with an additional 122,700 shares bought in Q2. He views Natera's Signatera cancer-testing business as resilient to economic downturns, focusing on its strong revenue growth and rising test volumes. Natera reported Q2 revenue of $752.8 million, up 37.7% year-over-year and beating estimates, with oncology test volume jumping 57.2%. The company also raised its full-year revenue guidance to $2.85 billion-$2.91 billion and expects positive cash flow for the full year. However, the stock trades at a high valuation, depends on insurance reimbursement, and faces increasing competition.